• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Breakthrough Properties Acquires Majority Interest in Callan Ridge, A Newly-Constructed, Fully-Leased Life Science Campus in Torrey Pines

    1/10/24 4:15:00 PM ET
    $BMY
    $PEAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate
    Get the next $BMY alert in real time by email

    The Acquisition, Via a Strategic Joint Venture with Healthpeak Properties, Further Accelerates Breakthrough's Growth in Premier Biotech Hubs

    SAN DIEGO, Calif., Jan. 10, 2024 /PRNewswire/ -- Breakthrough Properties ("Breakthrough"), a leading global life sciences real estate developer, today announced it has acquired a majority interest in Callan Ridge, a two-building Class A life science campus nearing completion in San Diego's preeminent Torrey Pines cluster. The 185,000-square-foot campus is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company (NYSE:BMY), through April 2035.

    Callan Ridge

    Breakthrough, which is a joint venture of global developer Tishman Speyer and biotechnology investment firm Bellco Capital, will own a 65% interest in Callan Ridge, while the project's developer, Healthpeak Properties (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, will retain a 35% interest.

    The three-story campus, which commenced construction in 2021, incorporates a wide range of sustainable building features, including electrochromic windows, photovoltaic glass panels, recycled steel and concrete, drought-tolerant landscaping and the largest single-building green roof in San Diego. The joint venture will pursue LEED Gold certification upon full completion of the development.  Ideally situated adjacent to the Torrey Pines Science Park and in close proximity to San Diego's leading research institutes, Callan Ridge also features unobstructed panoramic views of the Torrey Pines State Natural Reserve.

    "Callan Ridge presented us with a unique opportunity to acquire a newly-developed, trophy quality research campus in the heart of Torrey Pines – where Class A assets rarely become available – while also forming a new strategic partnership with the team at Healthpeak," said Breakthrough Properties Executive Vice President and Chief Investment Officer Daniel D'Orazi.  "Torrey Pines is one of the nation's leading biotech submarkets offering a dynamic ecosystem of research institutes, early-stage innovation and big pharma, proving throughout cycles to be one of the most sought-after clusters in the world."

    Breakthrough is one of the most active players in global life science real estate, with a total portfolio and pipeline of more than five million square feet across seven leading biotech clusters in the U.S. and Europe. In San Diego, Breakthrough is also nearing completion on its 10-acre Torrey View by Breakthrough campus, which will be anchored by a diverse mix of biotech users including a new innovation center for Becton, Dickinson and Company.  Breakthrough also owns and operates Torrey Plaza in San Diego, a three-building life science campus within the Del Mar Heights submarket which is the inaugural home of Breakthrough's StudioLabs platform. 

    About Breakthrough Properties (www.btprop.com)

    Formed in 2019 as a joint venture between global real estate owner, developer, and investor Tishman Speyer and biotechnology investment firm Bellco Capital, Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. Breakthrough Properties' mission is to acquire, develop and operate the best life science properties in leading urban technology centers around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/breakthrough-properties-acquires-majority-interest-in-callan-ridge-a-newly-constructed-fully-leased-life-science-campus-in-torrey-pines-302031868.html

    SOURCE Breakthrough Properties

    Get the next $BMY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMY
    $PEAK

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    11/13/2025$45.00Sector Perform
    Scotiabank
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Bristol-Myers Squibb Company
    $BMY
    12/10/2024$63.00Neutral
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    11/15/2024Peer Perform
    Wolfe Research
    Bristol-Myers Squibb Company
    $BMY
    11/13/2024Neutral → Outperform
    Daiwa Securities
    More analyst ratings

    $BMY
    $PEAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Bristol-Myers with a new price target

    Scotiabank initiated coverage of Bristol-Myers with a rating of Sector Perform and set a new price target of $45.00

    11/13/25 9:12:36 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Bristol-Myers from Outperform to Neutral and set a new price target of $42.00

    8/5/25 7:09:09 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

    Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

    4/22/25 8:00:39 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $PEAK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $PEAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP, Chief Commercial Officer Lenkowsky Adam

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    11/4/25 5:19:52 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. converted options into 2,964 shares, disposed of 544 shares and covered exercise/tax liability with 1,238 shares (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    11/4/25 5:18:07 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Digital & Tech Off. Meyers Gregory Scott converted options into 6,281 shares and covered exercise/tax liability with 2,665 shares, increasing direct ownership by 22% to 19,718 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    11/4/25 5:15:43 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $PEAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/19/25 7:19:54 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $PEAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb"), today announced the accepted amounts and pricing terms of the previously announced tender offers to purchase for cash its outstanding notes listed in the tables below. The outstanding debt securities listed in (i) the first table below labeled "Pool 1" are referred to collectively as the "Pool 1 Notes" and (ii) the second table below labeled "Pool 2" are referred to collectively as the "Pool 2 Notes." The Pool 1 Notes and the Pool 2 Notes are referred to collectively as the "Notes" and each series of Notes is referred to as a "series." We refer to each offer to purchase a series of Notes for cash as an "Offer," the offers t

    11/18/25 2:25:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers

    Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb"), today announced the early participation results, as of 5:00 p.m. (New York City time) on November 17, 2025, (the "Early Tender Deadline") of the previously announced tender offers to purchase for cash its outstanding notes listed in the tables below. Bristol Myers Squibb also announced that it is (i) decreasing the maximum aggregate purchase price of the Pool 1 Notes (as defined below) it will accept for purchase from the previously announced amount of $4,000,000,000 to an amount sufficient (the "Amended Pool 1 Maximum") to accept for purchase all Pool 1 Notes that were validly tendered and not validly withdrawn prior to the

    11/17/25 10:33:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Update on Phase 3 Librexia ACS Trial

    Independent, scheduled review finds Librexia ACS trial unlikely to meet primary efficacy endpoint, leading to decision to discontinue trial Librexia AF and Librexia STROKE studies continue as planned, with data expected in 2026 Milvexian continues to have potential as a multi-billion-dollar asset that could redefine anticoagulant therapy for thrombotic diseases Bristol Myers Squibb (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS) event. The d

    11/14/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $PEAK
    SEC Filings

    View All

    Bristol-Myers Squibb Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    11/18/25 4:41:56 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form CERT filed by Bristol-Myers Squibb Company

    CERT - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    11/12/25 10:06:53 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers Squibb Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    11/10/25 4:06:36 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $PEAK
    Leadership Updates

    Live Leadership Updates

    View All

    Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

    Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company's early-stage and late-stage product development across all therapeutic areas. "We are thrilled to welcome Cristian to Bristol Myers Squibb," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "His d

    7/25/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

    Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

    5/6/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

    Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

    3/20/25 8:00:00 AM ET
    $APLS
    $BIIB
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BMY
    $PEAK
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported third quarter 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed third quarter 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives

    10/30/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

    Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristo

    9/19/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on November 3, 2025, to stockholders of record at the close of business on October 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on December 1, 2025, to stockholders of record at the close of business on November 4, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discov

    9/17/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $PEAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Healthpeak Properties Inc. (Amendment)

    SC 13G/A - HEALTHPEAK PROPERTIES, INC. (0000765880) (Subject)

    2/13/24 5:06:13 PM ET
    $PEAK
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G/A filed by Healthpeak Properties Inc. (Amendment)

    SC 13G/A - HEALTHPEAK PROPERTIES, INC. (0000765880) (Subject)

    1/30/24 11:08:50 AM ET
    $PEAK
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

    SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

    2/9/23 11:12:40 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care